Use of biomarkers to determine whether a subject has sustained, may have sustained or is suspected of sustaining a subacute acquired brain injury (abi)
US-2024337668-A1 · Oct 10, 2024 · US
Methods and compositions for eliciting an amyloid-selective immune response
US9535076B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-9535076-B2 |
| Application number | US-200913055899-A |
| Country | US |
| Kind code | B2 |
| Filing date | Jul 27, 2009 |
| Priority date | Sep 12, 2002 |
| Publication date | Jan 3, 2017 |
| Grant date | Jan 3, 2017 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
The present invention involves methods and compositions for treating, preventing, and diagnosing amyloid-associated diseases and conditions, as well as methods and compositions for making antigens that elicit antibodies which selectively or specifically bind amyloid prefibrillar oligomers or protofibrillar aggregates over monomers or fibrils of the same amyloid.
First claim
Opening claim text (preview).
What is claimed is: 1. A composition comprising a modified or unmodified synthetic peptide or epitope comprising a fusion protein having an amino acid sequence joined to a surface of a particle, film or sheet in a manner which causes the peptide or epitope to be constrained in a conformation that allows it to a) bind an antibody that selectively or specifically binds to a prefibrillar aggregate comprising a naturally occurring amyloid peptide without binding substantially to monomers or fibrils of the amyloid peptide or b) induce production in a mammal of an antibody that selectively or specifically binds to a prefibrillar aggregate comprising a naturally occurring amyloid peptide without binding substantially to monomers or fibrils of the amyloid peptide, wherein the peptide or epitope comprises alternating polar and non-polar amino acid residues and the surface of the particle, film or sheet comprises a material selected from the group consisting of gold, zinc, cadmium, tin, titanium, silver, selenium, gallium, indium, arsenic, silicon, mixtures thereof and combinations thereof. 2. A composition according to claim 1 wherein said fusion protein comprises an antigenically effective portion of a carrier protein. 3. A composition according to claim 1 wherein said fusion protein comprises a carrier protein selected from the group consisting of a serum albumin, an immunoglobulin molecule, thyroglobulin, ovalbumin, a toxoid, a cytokine, a chemokine and a transmembrane transport protein. 4. A composition according to claim 1 wherein said composition comprises an adjuvant. 5. A composition according to claim 4 wherein the adjuvant comprises an aluminum salt. 6. A composition according to claim 4 wherein said adjuvant comprises an oil-in-water emulsion. 7. A composition according to claim 1 wherein the surface of the particle, film or sheet comprises gold. 8. A composition according to claim 1 wherein the particle, film or sheet comprises a gold microsphere. 9. A composition comprising SEQ ID NO: 10. 10. A composition comprising SEQ ID NO: 11. 11. A composition comprising SEQ ID NO: 12. 12. A composition comprising SEQ ID NO: 13.
Assignees
Inventors
Classifications
Immunostimulants · CPC title
Inorganic adjuvants · CPC title
Nervous system antigens; Prions · CPC title
having 12 to 20 amino acids (gastrins C07K14/595; somatostatins C07K14/655; melanotropins C07K14/68) · CPC title
Emulsions, e.g. Freund's adjuvant, MF59 · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US9535076B2 cover?
- The present invention involves methods and compositions for treating, preventing, and diagnosing amyloid-associated diseases and conditions, as well as methods and compositions for making antigens that elicit antibodies which selectively or specifically bind amyloid prefibrillar oligomers or protofibrillar aggregates over monomers or fibrils of the same amyloid.
- Who is the assignee on this patent?
- Kayed Rakez, Glabe Charles G, Univ California
- What technology area does this patent fall under?
- Primary CPC classification G01N33/6896. Mapped technology areas include Physics.
- When was this patent published?
- Publication date Tue Jan 03 2017 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 8 related publications on this page (citations in our corpus or others sharing the same primary CPC).